source
- Disc Medicine’s Phase 3 data revives rejected rare‑disease drug as China tightens biotech ownership rulesDisc Medicine announced that its Phase 3 trial of a previously rejected rare‑disease therapy showed positive results, effectively rescuing the program and positioning it for another submission to t…
- Hologic acquires Spain’s Reveal Genomics to expand breast cancer genomic testingHologic, a medical‑technology company, announced it will acquire precision‑oncology firm Reveal Genomics, based in Spain. Reveal Genomics develops advanced genomic diagnostic tests, notably the HE…